Exelixis Reports Completion of Patient Enrollment in P-III (CONTACT-03) Trial of Cabometyx (cabozantinib) + atezolizumab for Metastatic RCC
Shots:
- The P-III (CONTACT-03) trial evaluates the efficacy & safety of cabozantinib + atezolizumab vs cabozantinib alone in a ratio (1:1) in 523 patients with LA or metastatic clear cell or non-clear cell RCC who progressed during or following treatment with an ICI. The trial is sponsored by Roche & co-funded by Exelixis
- The 1EPs of the trial are OS & PFS as assessed by IRR. The 2EPs include PFS, ORR & DoR as assessed by investigators
- Cabometyx is approved in the US for advanced RCC, HCC, for patients with advanced RCC as a 1L treatment in combination with nivolumab & for LA or metastatic differentiated thyroid cancer. The therapy is also approved in the EU & and other and regions globally
Ref: Businesswire | Image: Pharma Advancement
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com